The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 21 rounds in the feed, most often in Biotech.
Venture capitalthecolumngroup.comRounds from 2015-12-03 to 2026-10-23
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Hexagon Bio A biopharmaceutical company pioneering the discovery of novel payload mechanisms for antibody-drug conjugates (ADCs) | Series C Verified against 4 of 14 sources | $62M | 2026-10-23 | [ LEAD ] |
TriGemX Bio A biotechnology company focused on developing a medicines for the treatment of migraine | Funding round |
| $94M |
| 2026-10-01 |
| [ LEAD ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series E Verified against 5 sources | $92.5M | 2026-09-16 | [ LEAD ] |
Tortugas Neuroscience Tortugasneuro develops therapies focused on brain health, targeting patients with brain disorders. | Seed Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $106M | 2026-04-21 | [ PART ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Series B ext. Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2026-03-05 | [ PART ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-12-18 | [ LEAD ] |
Nilo Nilo Therapeutics develops medicines that target neural circuits to restore immune balance in autoimmune and inflammatory disease. | Series A Verified against 1 of 4 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $101M | 2025-10-08 | [ LEAD ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Funding round Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $102M | 2025-04-03 | [ PART ] |
Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches. | Series D Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $350.7M | 2025-02-26 | [ PART ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Seed Developing, 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2024-02-08 | [ PART ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Funding round Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $40M | 2023-12-19 | [ PART ] |
Hexagon Bio A biopharmaceutical company pioneering the discovery of novel payload mechanisms for antibody-drug conjugates (ADCs) | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $77.3M | 2023-02-13 | [ PART ] |
Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $517.8M | 2022-01-06 | [ PART ] |
Hexagon Bio A biopharmaceutical company pioneering the discovery of novel payload mechanisms for antibody-drug conjugates (ADCs) | Funding round Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $61M | 2021-09-22 | [ PART ] |
Atavistik Bio Atavistik Bio develops novel allosteric therapeutics for serious diseases, particularly targeting proteins involved in conditions like Hereditary Hemorrhagic Telangiectasia (HHT). | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $60M | 2021-08-24 | [ LEAD ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Funding round Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $41.5M | 2021-06-22 | [ LEAD ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series C Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $66M | 2021-06-16 | [ LEAD ] |
Eikon Therapeutics Eikon is a late-stage clinical biopharmaceutical company focused on inventing and developing breakthrough therapeutics for serious illnesses through innovative scientific and engineering approaches. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $148M | 2021-05-05 | [ LEAD ] |
Hexagon Bio A biopharmaceutical company pioneering the discovery of novel payload mechanisms for antibody-drug conjugates (ADCs) | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $47M | 2020-09-15 | [ LEAD ] |
Circle Pharma A biopharmaceutical company advancing CID-165 for ER-positive breast cancer | Series B Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $45M | 2020-03-17 | [ LEAD ] |
Neurona Therapeutics Cell therapies for targeted repair of dysfunctional neural circuits underlying chronic neurological diseases. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $23.5M | 2015-12-03 | [ LEAD ] |